CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Understand what constitutes the cheapest index fund and how expense ratios affect long-term growth. Compare options to choose wisely.
12,952 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
As markets wobble in 2026, investors are turning to a core portfolio cornerstone built on durable, recurring revenue....
Real estate cycles linger, but today’s price pressures aren’t a carbon copy of 2008. Learn how Ken McElroy analyzes c...
Retirees face a shifting rate landscape. This guide explains how a possible 2026 rate rise could affect income, withd...
Retirees are increasingly aiming for dependable cash flow without depleting principal. A $850,000 portfolio that quie...
When Netflix reportedly missed out on Roku, investors asked: what does this mean for the company’s future profits and...
A high-profile health hiccup on opening night offers a blunt lesson in personal finance for fans and performers. Lear...
Vietnam is turning culture into a growth engine, aiming for 7% of GDP by 2030 and double-digit expansion in cultural ...
Political discussions around Social Security could reshape retirement planning. This article breaks down what the Spe...
Bitcoin’s wild moves test every investor, even high-profile ones. This piece dives into Dave Portnoy’s experience, th...
Oil markets roiled by Hormuz disruptions push energy ETFs past the 50% mark for the year, prompting a closer look at ...
In June, SMCI faced a sharp 36% slide as investors weighed dilution, changing AI demand tides, and macro uncertainty....